Overview

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai First Maternity and Infant Hospital
Treatments:
Atosiban
Oxytocin
Vasotocin